Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
20%(1 trials)

Phase Distribution

Ph not_applicable
2
22%
Ph phase_2
4
44%
Ph phase_4
2
22%
Ph phase_1
1
11%

Phase Distribution

1

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
4(44.4%)
Phase 4Post-market surveillance
2(22.2%)
N/ANon-phased studies
2(22.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(5)
Other(3)

Detailed Status

Completed5
unknown3
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (11.1%)
Phase 24 (44.4%)
Phase 42 (22.2%)
N/A2 (22.2%)

Trials by Status

completed556%
unknown333%
not_yet_recruiting111%

Recent Activity

0 active trials
Showing 5 of 9
not_yet_recruitingphase_2

Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL

NCT07185373
unknownnot_applicable

Teniposide Incorporating Bu/Cy Conditioning Regimen for HLH With Central Nervous System Involvemen

NCT06048107
completedphase_2

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

NCT01700946
completedphase_4

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)

NCT00198991
completedphase_4

Treatment of High Risk Adult Acute Lymphoblastic Leukemia

NCT00853008
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07185373Phase 2

Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL

Not Yet Recruiting
NCT06048107Not Applicable

Teniposide Incorporating Bu/Cy Conditioning Regimen for HLH With Central Nervous System Involvemen

Unknown
NCT01700946Phase 2

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Completed
NCT00198991Phase 4

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)

Completed
NCT00853008Phase 4

Treatment of High Risk Adult Acute Lymphoblastic Leukemia

Completed
NCT00002531Phase 2

Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia

Unknown
NCT00343369Not Applicable

Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia

Unknown
NCT00004231Phase 2

Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Completed
NCT00004916Phase 1

Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9